Close to the Edge: Regeneron’s George Yancopoulos and Aris Baras Discuss Company, COVID-19

Yancopoulos and Baras discussed Regeneron's growth, notable drugs in the company's portfolio, the success of the Regeneron Genetics Center, and new technologies that will change the face of drug development over the next decade or so, such as RNAi and CRISPR . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleJumping Through Hoops: Cryo-EM Uncovers CRISPR-Transposons
Next articleBenefits of Automating NGS Sample Preparation